A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Apr 21, 2016

AMGEN ASTELLAS BIOPHARMA AND ASTELLAS INTRODUCE REPATHA® (EVOLOCUMAB) FOR THE TREATMENT OF HIGH CHOLESTEROL

FIrst PCSK9 Inhibitor in Japan

TOKYO (April 21, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Eiichi Takahashi, “Amgen Astellas”) and Astellas Pharma Inc....

Read more about AMGEN ASTELLAS BIOPHARMA AND ASTELLAS INTRODUCE REPATHA® (EVOLOCUMAB) FOR THE TREATMENT OF HIGH CHOLESTEROL
Apr 18, 2016

Astellas Supports the 2016 Kumamoto Earthquake Relief Efforts

Tokyo, April 18, 2016– Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, “Astellas”) would like to express our deepest sympathy to the victims of the 2016...

Read more about Astellas Supports the 2016 Kumamoto Earthquake Relief Efforts
Apr 8, 2016

Certain media coverage related to Astellas

Tokyo, April 8, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that certain media coverage related to transfer of business of the...

Read more about Certain media coverage related to Astellas
Apr 7, 2016

CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide)

-- TERRAIN Trial Showed Statistically Significant PFS Improvement with Enzalutamide Versus Bicalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer --

Read more about CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide)
Apr 1, 2016

Astellas Enters a New Collaborative Research Agreement with AIST to Discover Anti-protozoan Parasite Drugs for the Treatment of Chagas' disease, one of Neglected Tropical Diseases

Tokyo, April 1, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") today announced that it has signed a new collaborative research agreement with the...

Read more about Astellas Enters a New Collaborative Research Agreement with AIST to Discover Anti-protozoan Parasite Drugs for the Treatment of Chagas' disease, one of Neglected Tropical Diseases
Apr 1, 2016

Establishment and Start of Operations of Malaysia Subsidiary and Umbrella Organization Covering South East and South Asia Regions

Read more about Establishment and Start of Operations of Malaysia Subsidiary and Umbrella Organization Covering South East and South Asia Regions
Apr 1, 2016

Astellas and LEO Pharma Close Transaction to Transfer Global Dermatology Business

Read more about Astellas and LEO Pharma Close Transaction to Transfer Global Dermatology Business
Mar 29, 2016

Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries

Tokyo and Osaka, March 29, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Mitsubishi Tanabe Pharma Corporation (President and Representative Director:...

Read more about Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries
Mar 25, 2016

Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer

Read more about Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Mar 22, 2016

POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING ROMOSOZUMAB IN MEN WITH OSTEOPOROSIS

BRIDGE Study Met Primary and All Secondary Endpoints

TOKYO (March 22, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Eiichi Takahashi, “Amgen Astellas”) and Astellas Pharma Inc....

Read more about POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING ROMOSOZUMAB IN MEN WITH OSTEOPOROSIS
Mar 16, 2016

Astellas Selected as a Nadeshiko Brand Component for Excellence in Providing Opportunities for Women

- First time for a Pharmaceutical Company to be named to both Diversity Management Selection 100 and Nadeshiko Brand -

Read more about Astellas Selected as a Nadeshiko Brand Component for Excellence in Providing Opportunities for Women
Mar 4, 2016

Astellas Announces Personnel Changes

Read more about Astellas Announces Personnel Changes
Mar 2, 2016

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Mar 1, 2016

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Mar 1, 2016

Astellas Announces Personnel Changes and Organizational Change

Read more about Astellas Announces Personnel Changes and Organizational Change
Mar 1, 2016

Astellas Announces Management Structure Change

Read more about Astellas Announces Management Structure Change
Feb 29, 2016

Astellas Receives Approval for a Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan

Read more about Astellas Receives Approval for a Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan
Feb 24, 2016

Astellas Submits New Drug Application for Linaclotide, Treatment for Irritable Bowel Syndrome with Constipation, in Japan

Tokyo, February 24, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it submitted a new drug application for a guanylate...

Read more about Astellas Submits New Drug Application for Linaclotide, Treatment for Irritable Bowel Syndrome with Constipation, in Japan
Feb 22, 2016

FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Metastatic Castration-resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Versus Bicalutamide

Read more about FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Metastatic Castration-resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Versus Bicalutamide
Feb 10, 2016

Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries

Read more about Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries
Feb 10, 2016

Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidaries

Read more about Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidaries
Feb 1, 2016

Astellas and CLINO Announce License Agreement to Develop and Commercialize Gene Therapy to Treat Retinitis Pigmentosa

Tokyo and Miyagi, February 1st, 2016 - Astellas Pharma Inc. (TSE : 4503, President and CEO : Yoshihiko Hatanaka, “Astellas”) and CLINO Corporation (President : Noriaki Satake, “CLINO”)...

Read more about Astellas and CLINO Announce License Agreement to Develop and Commercialize Gene Therapy to Treat Retinitis Pigmentosa
Jan 29, 2016

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Acquisition of Own Shares
Jan 23, 2016

POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN OSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

FRAME Study Met All Primary Endpoints by Reducing the Incidence of New Vertebral Fracture Through 12 and 24 Months

Read more about POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN OSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
Jan 22, 2016

REPATHA® (EVOLOCUMAB) APPROVED AS FIRST PCSK9 INHIBITOR IN JAPAN FOR THE TREATMENT OF HIGH CHOLESTEROL

Important Milestone for Certain Japanese Patients With Uncontrolled LDL Cholesterol

Read more about REPATHA® (EVOLOCUMAB) APPROVED AS FIRST PCSK9 INHIBITOR IN JAPAN FOR THE TREATMENT OF HIGH CHOLESTEROL
Jan 22, 2016

Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics - ASTELLAS IS COMMITTED TO TRANSACTION, ACQUISITION OF OCATA IS A STRATEGIC PRIORITY -

Tokyo and Massachusetts, January 22, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO:...

Read more about Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics - ASTELLAS IS COMMITTED TO TRANSACTION, ACQUISITION OF OCATA IS A STRATEGIC PRIORITY -
Jan 7, 2016

Extension of agreement on Telmisartan (Micardis® family)

Read more about Extension of agreement on Telmisartan (Micardis® family)
Dec 18, 2015

Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics

Tokyo and Massachusetts, December 18, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO:...

Read more about Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
Dec 10, 2015

Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy

Houston and Tokyo, December 10, 2015 - Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM, “Bellicum”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that Agensys, Inc....

Read more about Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy
Dec 2, 2015

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Dec 1, 2015

Astellas Announces Personnel Change

Read more about Astellas Announces Personnel Change
Dec 1, 2015

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Nov 30, 2015

Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan

Read more about Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan
Nov 20, 2015

Astellas Commences Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics

Tokyo, November 20, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has commenced, through its indirect wholly-owned...

Read more about Astellas Commences Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
Nov 18, 2015

Presentation for Astellas to Acquire Ocata Therapeutics

Astellas added minor revisions into the presentation for Astellas to acquire Ocata Therapeutics which was disclosed on November 10th, 2015. Presentation for Astellas to Acquire Ocata Therapeutics...

Read more about Presentation for Astellas to Acquire Ocata Therapeutics
Nov 13, 2015

Named to 2015 Climate Disclosure Leadership Index -Recognized for perfect disclosure score for climate change information -

Tokyo, November 13, 2015 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been named for the first time to the CDP1) Japan 500 Climate...

Read more about Named to 2015 Climate Disclosure Leadership Index -Recognized for perfect disclosure score for climate change information -
Nov 10, 2015

The 2nd Year Results of C-OPERA, a Study of Anti-TNF-alpha Antibody Certolizumab Pegol, Announced at 2015 ACR/ARHP Annual Meeting

- The Clinical benefit of initial 1-year CZP treatment was maintained after discontinuation up to another 1-year -

Read more about The 2nd Year Results of C-OPERA, a Study of Anti-TNF-alpha Antibody Certolizumab Pegol, Announced at 2015 ACR/ARHP Annual Meeting
Nov 10, 2015

Acquisition of Ocata Therapeutics

New Step Forward in Ophthalmology with Cell Therapy Approach

Read more about Acquisition of Ocata Therapeutics
Oct 30, 2015

Astellas Concludes Agreement with MicroBiopharm Japan on Transfer of Kiyosu Plant Business

Read more about Astellas Concludes Agreement with MicroBiopharm Japan on Transfer of Kiyosu Plant Business
Oct 28, 2015

Astellas Announces Acquisition of Own Shares

Read more about Astellas Announces Acquisition of Own Shares
Oct 28, 2015

Astellas Initiates Phase 3 Registration Trial of gilterritnib (ASP2215) in Relapsed of Refractory Acute Myeloid Leukemia Patients

Read more about Astellas Initiates Phase 3 Registration Trial of gilterritnib (ASP2215) in Relapsed of Refractory Acute Myeloid Leukemia Patients
Oct 9, 2015

Astellas Pharma and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax™ Products for Allergic Disease

Hershey, PA & Rockville, MD and Tokyo, Japan, October 9, 2015 – Immunomic Therapeutics, Inc. (“Immunomic Therapeutics”), a company developing next generation vaccines based on the LAMP-vax...

Read more about Astellas Pharma and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax™ Products for Allergic Disease
Oct 5, 2015

Astellas Donates 6 Wheelchair Vans through the Flying Star Fund, an Employee-Led Social Contribution Fund

Read more about Astellas Donates 6 Wheelchair Vans through the Flying Star Fund, an Employee-Led Social Contribution Fund
Sep 30, 2015

Submission of a Supplemental New Drug Application for ASP1585 Granule,a Treatment for Hyperphosphatemia, in Japan

Tokyo, September 30, 2015 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it submitted a supplemental new drug application for...

Read more about Submission of a Supplemental New Drug Application for ASP1585 Granule,a Treatment for Hyperphosphatemia, in Japan
Sep 30, 2015

Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain

Tokyo and North Brunswick, N.J., Sept 30th, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Chromocell Corporation (CEO: Christian Kopfli,...

Read more about Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain
Sep 18, 2015

Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Fifth Consecutive Year

Read more about Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Fifth Consecutive Year
Sep 17, 2015

Astellas Supports Relief Efforts Following Typhoon in Eastern and Northern Japan

Read more about Astellas Supports Relief Efforts Following Typhoon in Eastern and Northern Japan
Sep 8, 2015

Astellas Named to FTSE4Good Sustainability Index for the Fourth Consecutive Year

Read more about Astellas Named to FTSE4Good Sustainability Index for the Fourth Consecutive Year
Sep 7, 2015

Astellas donates ambulances on First-Aid Day (September 9)

-45th donation since 1970, totaling 234 ambulances

Read more about Astellas donates ambulances on First-Aid Day (September 9)
Aug 27, 2015

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Aug 20, 2015

Astellas Announces Changes in Personnel and Sales and Marketing Structure in Japan

Read more about Astellas Announces Changes in Personnel and Sales and Marketing Structure in Japan
Jul 31, 2015

Astellas Establishes New Real World Informatics and Analytics Function

Tokyo, Japan, July 31, 2015 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, collectively with its affiliates, hereinafter called “Astellas”) announced the launch of the Real...

Read more about Astellas Establishes New Real World Informatics and Analytics Function
Jul 31, 2015

Astellas Announces Acquisition of Own Shares

Read more about Astellas Announces Acquisition of Own Shares
Jul 30, 2015

Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections

NORTHBROOK, Ill., July 30, 2015 – Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole,...

Read more about Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections
Jul 23, 2015

Astellas Initiates Collaborative Research with National Institute of Advanced Industrial Science and Technology by Utilizing Highly Advanced IT Drug-Discovery Technologies

- Aiming for early discovery of compounds in the areas of Ophthalmology and Nephrology by merging approximately 10,000 of protein-ligand complex structural information and highly advanced IT drug-discovery technologies -

Read more about Astellas Initiates Collaborative Research with National Institute of Advanced Industrial Science and Technology by Utilizing Highly Advanced IT Drug-Discovery Technologies
Jul 22, 2015

“Cell therapy using human iPSC-derived renal progenitors ameliorates acute kidney injury in mice” published in “Stem Cells Translational Medicine” on line

Read more about “Cell therapy using human iPSC-derived renal progenitors ameliorates acute kidney injury in mice” published in “Stem Cells Translational Medicine” on line
Jul 16, 2015

The Netherlands Decorates Masafumi Nogimori, Representative Director and Chairman of Astellas with "Officer in the Order of Oranje-Nassau" Royal Decoration

Read more about The Netherlands Decorates Masafumi Nogimori, Representative Director and Chairman of Astellas with "Officer in the Order of Oranje-Nassau" Royal Decoration
Jul 13, 2015

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Jul 1, 2015

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Jul 1, 2015

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Jun 15, 2015

Results of Additional Analysis of Data from Japanese Clinical Trial of Anti-TNF-alpha Antibody Certolizumab Pegol Announced at 2015 EULAR Annual European Congress of Rheumatology

Read more about Results of Additional Analysis of Data from Japanese Clinical Trial of Anti-TNF-alpha Antibody Certolizumab Pegol Announced at 2015 EULAR Annual European Congress of Rheumatology
Jun 2, 2015

Astellas and Anokion to Collaborate on Immune Tolerance Therapeutics - Kanyos Bio established to develop products for Celiac Disease and Type 1 Diabetes -

Astellas Pharma Inc. (“Astellas”; TSE 4503, headquarters: Tokyo; President and CEO Yoshihiko Hatanaka) and Anokion SA (“Anokion“, headquarters: Lausanne; Chairman Jeffrey A. Hubbell) today...

Read more about Astellas and Anokion to Collaborate on Immune Tolerance Therapeutics - Kanyos Bio established to develop products for Celiac Disease and Type 1 Diabetes -
Jun 2, 2015

NEW ENZALUTAMIDE DATA IN TRIPLE-NEGATIVE BREAST CANCER PRESENTED AT THE 2015 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

TOKYO and NORTHBROOK, Ill. – June 1, 2015 – Astellas Pharma Inc. (Tokyo: 4503) announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for...

Read more about NEW ENZALUTAMIDE DATA IN TRIPLE-NEGATIVE BREAST CANCER PRESENTED AT THE 2015 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
Jun 1, 2015

Astellas Announces Status of Acquisition of Own Shares

Read more about Astellas Announces Status of Acquisition of Own Shares
May 30, 2015

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability and Efficacy Data for ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Read more about Astellas Announces Preliminary Phase 1/2 Safety, Tolerability and Efficacy Data for ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
May 27, 2015

Strategic Plan 2015-2017

Building Resilience for Sustainable Growth

Read more about Strategic Plan 2015-2017
May 26, 2015

Astellas: Strategic Plan 2015-2017

Read more about Astellas: Strategic Plan 2015-2017
May 26, 2015

Announcement of Approval of Additional Indication for the TNF-α inhibitor Certolizumab Pegol (Generic Name) in Japan

Read more about Announcement of Approval of Additional Indication for the TNF-α inhibitor Certolizumab Pegol (Generic Name) in Japan
May 26, 2015

Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan

Read more about Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan
May 26, 2015

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Acquisition of Own Shares
May 17, 2015

Mirabegron as Add-on Treatment to Solifenacin Therapy Demonstrated Superior Results to Solifenacin Monotherapy in Beside Trail

Data Presented in Pienary Sessions at AUA 2015

Read more about Mirabegron as Add-on Treatment to Solifenacin Therapy Demonstrated Superior Results to Solifenacin Monotherapy in Beside Trail
May 11, 2015

Astellas Announces Cancellation of Treasury Shares

Read more about Astellas Announces Cancellation of Treasury Shares
May 11, 2015

Notice Regarding the Introduction of a Performance-linked Stock Compensation Scheme

Read more about Notice Regarding the Introduction of a Performance-linked Stock Compensation Scheme
May 8, 2015

Astellas Supports Nepal Earthquake Relief Efforts

Tokyo, May 8, 2015– Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, “Astellas”) would like to express our deepest sympathy to the victims of Nepal...

Read more about Astellas Supports Nepal Earthquake Relief Efforts
Apr 24, 2015

Astellas Announces Personnel Change

Read more about Astellas Announces Personnel Change
Apr 23, 2015

The Results of Japanese Clinical Trials of Anti-TNF-alpha Antibody Certolizumab Pegol were Announced at Leading Rheumatology Meeting 2015 in Japan

Tokyo, Japan, 23 April, 2015-The additional analyses of C-OPERA, and long-term safety and efficacy over 4 years in J-RAPID and HIKARI studies were reported at the Annual General Assembly and...

Read more about The Results of Japanese Clinical Trials of Anti-TNF-alpha Antibody Certolizumab Pegol were Announced at Leading Rheumatology Meeting 2015 in Japan
Apr 23, 2015

Astellas Announces Consolidated Business Forecasts for Fiscal Year 2014

Read more about Astellas Announces Consolidated Business Forecasts for Fiscal Year 2014
Apr 23, 2015

Astellas Nominates Director and Audit & Supervisory Board Member

Read more about Astellas Nominates Director and Audit & Supervisory Board Member
Apr 22, 2015

Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics - Exclusive Collaboration Includes Option for Astellas to Acquire Potenza -

Tokyo and Cambridge, MA – April 22, 2015 -- Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today...

Read more about Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics - Exclusive Collaboration Includes Option for Astellas to Acquire Potenza -
Apr 15, 2015

MSD and Astellas sign a memorandum of understanding regarding co-development and co-commercialization of combination product of JANUVIA® and Suglat®, oral treatments for type 2 diabetes

MSD K.K. (Head office: Tokyo; President: Tony Alvarez) and Astellas Pharma Inc. (Head office: Tokyo; President: Yoshihiko Hatanaka) signed a memorandum of understanding regarding co-development...

Read more about MSD and Astellas sign a memorandum of understanding regarding co-development and co-commercialization of combination product of JANUVIA® and Suglat®, oral treatments for type 2 diabetes
Apr 3, 2015

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia

TOKYO and HOUSTON – April 3, 2015 – Astellas Pharma Inc. (TSE: 4503) and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and...

Read more about MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia
Apr 3, 2015

ENZALUTAMIDE DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION FREE SURVIVAL COMPARED WITH BICALUTAMIDE IN STRIVE TRIAL

SAN FRANCISCO, CA and TOKYO, JAPAN – April 2, 2015 – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced topline results from the Phase 2 STRIVE trial...

Read more about ENZALUTAMIDE DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION FREE SURVIVAL COMPARED WITH BICALUTAMIDE IN STRIVE TRIAL
Apr 1, 2015

Astellas Celebrates 10th Anniversary

Tokyo, Japan, April 1, 2015 – Astellas Pharma Inc. (Tokyo:4503,“Astellas”) is pleased to announce that the Company will mark its 10th anniversary on April 1, 2015. Since being established in...

Read more about Astellas Celebrates 10th Anniversary
Mar 24, 2015

ASTELLAS AND MEDIVATION ANNOUNCE NEW ENZALUTAMIDE DATA PRESENTED DURING PLENARY PRESENTATIONS AT THE 2015 EUROPEAN ASSOCIATION OF UROLOGY CONGRESS

Read more about ASTELLAS AND MEDIVATION ANNOUNCE NEW ENZALUTAMIDE DATA PRESENTED DURING PLENARY PRESENTATIONS AT THE 2015 EUROPEAN ASSOCIATION OF UROLOGY CONGRESS
Mar 20, 2015

ANNOUNCEMENT OF MARKETING APPROVAL SUBMISSION TO MHLW (JAPAN) FOR LDL CHOLESTEROL-LOWERING MEDICATION EVOLOCUMAB

Read more about ANNOUNCEMENT OF MARKETING APPROVAL SUBMISSION TO MHLW (JAPAN) FOR LDL CHOLESTEROL-LOWERING MEDICATION EVOLOCUMAB
Mar 17, 2015

Astellas Submits Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan

Tokyo, March 17, 2015 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that it submitted a supplemental new drug application for...

Read more about Astellas Submits Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan
Mar 16, 2015

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Mar 9, 2015

Astellas Receives FDA Approval for CRESEMBA® (isavuconazonium sulfate) for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

NORTHBROOK, Ill., March 6th, 2015, – Astellas today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of CRESEMBA®...

Read more about Astellas Receives FDA Approval for CRESEMBA® (isavuconazonium sulfate) for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis
Feb 13, 2015

Astellas Pharma Launches the Newest Element in its Global Corporate Brand Campaign On CNN’s Global Broadcast Network

Read more about Astellas Pharma Launches the Newest Element in its Global Corporate Brand Campaign On CNN’s Global Broadcast Network
Feb 5, 2015

Enhancement of Astellas’ Management Structure

Read more about Enhancement of Astellas’ Management Structure
Feb 5, 2015

Astellas Announces Personnel Changes and Organization Changes

Read more about Astellas Announces Personnel Changes and Organization Changes
Feb 2, 2015

Graduate School of Medicine/Faculty of Medicine, Osaka University and Astellas establish joint research chair for R&D on next-generation cell therapy

Read more about Graduate School of Medicine/Faculty of Medicine, Osaka University and Astellas establish joint research chair for R&D on next-generation cell therapy
Feb 2, 2015

Astellas Announces Acquisition of Own Shares

Read more about Astellas Announces Acquisition of Own Shares
Feb 2, 2015

ASTELLAS BROADENS COMMITMENT TO CLINICAL TRIAL DATA TRANSPARENCY

Tokyo, Feb. 2, 2015—Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) announced today that the company will now make trial data available through www.clinicalstudydatarequest.com, an...

Read more about ASTELLAS BROADENS COMMITMENT TO CLINICAL TRIAL DATA TRANSPARENCY
Jan 30, 2015

Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Cedar Pollinosis

Hershey, PA & Rockville, MD and Tokyo, Japan. January 30, 2015 – Immunomic Therapeutics, Inc. (“Immunomic Therapeutics”), a company developing next generation vaccines based on the LAMP-vax...

Read more about Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Cedar Pollinosis
Jan 23, 2015

ENZALUTAMIDE PHASE 2 TERRAIN TRIAL DEMONSTRATED STATISTICALLY SIGNIFICANT INCREASE IN PFS AS COMPARED TO BICALUTAMIDE IN METASTATIC PROSTATE CANCER

SAN FRANCISCO, CA and TOKYO, JAPAN – January 22, 2015 – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced topline results from the Phase 2 TERRAIN trial...

Read more about ENZALUTAMIDE PHASE 2 TERRAIN TRIAL DEMONSTRATED STATISTICALLY SIGNIFICANT INCREASE IN PFS AS COMPARED TO BICALUTAMIDE IN METASTATIC PROSTATE CANCER
Jan 23, 2015

Astellas Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval of CRESEMBA® (isavuconazonium) for Treatment of Invasive Aspergillosis and Mucormycosis

NORTHBROOK, Ill., January 22, 2015, – Astellas today announced that the U.S. Food and Drug Administration’s (FDA) Anti-infective Drugs Advisory Committee voted unanimously to recommend...

Read more about Astellas Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval of CRESEMBA® (isavuconazonium) for Treatment of Invasive Aspergillosis and Mucormycosis
Jan 22, 2015

ENZALUTAMIDE PHASE 2 TERRAIN TRIAL DEMONSTRATED STATISTICALLY SIGNIFICANT INCREASE IN PFS AS COMPARED TO BICALUTAMIDE IN METASTATIC PROSTATE CANCER

Read more about ENZALUTAMIDE PHASE 2 TERRAIN TRIAL DEMONSTRATED STATISTICALLY SIGNIFICANT INCREASE IN PFS AS COMPARED TO BICALUTAMIDE IN METASTATIC PROSTATE CANCER
Dec 24, 2014

CYTOKINETICS AND ASTELLAS ANNOUNCE EXPANSION OF COLLABORATION FOR DEVELOPMENT OF CK-2127107 IN SPINAL MUSCULAR ATROPHY AND OTHER NEUROMUSCULAR INDICATIONS

Cytokinetics Expects to Receive Over $75 Million in Committed Capital and Reimbursements For Planned Activities

South San Francisco, CA, and Tokyo, December 23, 2014 – Cytokinetics, Incorporated (NASDAQ:CYTK) and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, "Astellas") announced today an amendment to...

Read more about CYTOKINETICS AND ASTELLAS ANNOUNCE EXPANSION OF COLLABORATION FOR DEVELOPMENT OF CK-2127107 IN SPINAL MUSCULAR ATROPHY AND OTHER NEUROMUSCULAR INDICATIONS
Dec 15, 2014

DATA PRESENTED FROM PHASE 2 STUDY OF ENZALUTAMIDE IN ADVANCED ANDROGEN-RECEPTOR POSITIVE, TRIPLE-NEGATIVE BREAST CANCER

SAN FRANCISCO, CA and TOKYO – December 12, 2014 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (Tokyo: 4503), announced today the presentation of Stage 1 and preliminary Stage 2...

Read more about DATA PRESENTED FROM PHASE 2 STUDY OF ENZALUTAMIDE IN ADVANCED ANDROGEN-RECEPTOR POSITIVE, TRIPLE-NEGATIVE BREAST CANCER

Show per page

Discover more

Media contacts

Return to media homepage

Subscribe to news alerts

Choose Language

News